文献速递癫痫神经重症与神经感染

新发难治性癫痫持续状态与病因明确癫痫持续状态的急性脑损伤

Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus.
PubMed 文献 · JAMA Neurol · 2026-01-01

这项国际横断面研究纳入78例隐源性NORSE、两个独立病因明确癫痫持续状态队列(211例和73例)及无癫痫持续状态对照,检测血清和脑脊液NfL与S100B。cNORSE的NfL显著高于eSE及对照,且随病程早期快速上升,S100B无差异。较高血清NfL与出院时不良功能结局独立相关,提示cNORSE急性神经轴索损伤更重且治疗窗口窄。

要点

  • cNORSE患者脑脊液NfL约为eSE队列的10倍,血清NfL约为4倍。
  • cNORSE血清NfL较慢性癫痫和健康对照高近20倍,且第1至3周快速上升。
  • 血清NfL升高与出院时不良功能结局独立相关,S100B无组间差异。

核心结论

  • cNORSE急性神经轴索损伤显著重于eSE和无癫痫持续状态对照,NfL早期快速上升提示治疗窗口窄。

研究设计与样本

  • 国际横断面研究,2013至2025年在美国36家、加拿大2家及意大利、法国、比利时各1家医院开展。
  • 纳入78例cNORSE和两个独立eSE队列(211例和73例),对照为慢性癫痫患者和健康参与者。
  • 检测血清和脑脊液NfL与S100B浓度,分析其与短期功能结局的关联。

主要发现

  • cNORSE脑脊液NfL中位数6408 pg/mL,eSE为694 pg/mL;血清NfL中位数231 pg/mL,eSE为55 pg/mL(P < .001)。
  • cNORSE血清NfL较慢性癫痫(中位数11 pg/mL)和健康对照(中位数7 pg/mL)高近20倍。
  • 血清与脑脊液NfL强相关(Spearman ρ = 0.75;P < .001),起病后第1、2、3周中位数分别为101、197、598 pg/mL(P < .001)。
  • S100B浓度组间无差异且无一致时间模式。
  • NfL区分cNORSE与eSE的AUROC为0.79(95% CI 0.68-0.90),区分无癫痫持续状态队列的AUROC为0.99(95% CI 0.78-1.00)。

临床怎么用

  • 血清NfL可作为cNORSE急性神经轴索损伤的候选生物标志物,辅助区分cNORSE与eSE。
  • NfL早期快速上升提示cNORSE需尽早采取有效且可能具有神经保护作用的干预。

局限性

  • 横断面设计无法确定NfL动态变化与结局的因果关系。
  • 样本来自特定国际中心,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Seizure-induced brain injury is central to the treatment urgency of new-onset refractory status epilepticus (NORSE). Identifying biomarkers that reflect ongoing neuronal damage could inform therapeutic timing and improve outcomes. OBJECTIVE: To quantify acute brain injury in patients with cryptogenic NORSE (cNORSE), etiology-defined status epilepticus (eSE), and chronic epilepsy. DESIGN, SETTING, AND PARTICIPANTS: This was an international cross-sectional study conducted between 2013 and 2025. Patients were enrolled at 36 hospitals in the US, 2 in Canada, and 1 in Italy, France, and Belgium. Patients with cNORSE and eSE for which biological samples were obtained during ongoing seizure activity were enrolled in the study. Comparison groups without status epilepticus comprised individuals with chronic epilepsy and healthy participants. None were excluded. EXPOSURES: Neurofilament light chain (NfL) and S100-beta (S100B) protein concentrations in serum and cerebrospinal fluid (CSF). MAIN OUTCOMES AND MEASURES: Degree of neuronal and glial damage, indexed by NfL and S100B levels, and their association with short-term functional outcomes. RESULTS: A total of 78 patients with cNORSE (mean [95% CI] age, 37 [30-41] years; 44 female [56%]) and 2 independent cohorts of 211 patients (mean [95% CI] age, 69 [66-71] years; 128 female [61%]) and 73 patients (mean [95% CI] age, 56 [45-65] years; 39 male [53%]) with eSE were included. NfL concentrations were markedly elevated in cNORSE-approximately 10-fold higher in CSF and 4-fold higher in serum-compared with the eSE cohorts (CSF: median [IQR], 6408 [1503-22 963] pg/mL compared with 694 [219-2389] pg/mL; serum: median [IQR], 231 [99-855] pg/mL compared with 55 [20-135] pg/mL; P <.001). Serum NfL levels were nearly 20-fold higher in cNORSE than in the cohort with epilepsy and in healthy controls (median [IQR], 11 [7-19 ] and 7 [5-14 ] pg/mL, respectively). Serum and CSF NfL levels were strongly correlated (Spearman ρ = 0.75; P < .001) and rose sharply between week 1 (median [IQR], 101 [51-137] pg/mL), week 2 (median [IQR], 197 [117-324] pg/mL), and week 3 (median [IQR], 598 [163-1000] pg/mL) after onset (P < .001). In contrast, S100B concentrations did not differ between groups and showed no consistent temporal pattern. NfL discriminated cNORSE from eSE (area under the receiver operating characteristic curve [AUROC], 0.79; 95% CI, 0.68-0.90) and from cohorts without status epilepticus (AUROC, 0.99; 95% CI, 0.78-1.00). Higher serum NfL was independently associated with poor functional outcome at discharge (Glasgow Outcome Scale extended score, 1-4; odds ratio, 1.01; 95% CI, 1.00-1.03; P = .03). CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study suggest that acute neuroaxonal injury, as reflected by elevated NfL levels, was substantially greater in cNORSE than in the cohorts with eSE and in controls without status epilepticus. The rapid early rise in NfL highlights a narrow therapeutic window, emphasizing the need for prompt, effective, and potentially neuroprotective interventions in cNORSE.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Meletti S, Hanin A, Giovannini G, et al. Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus. JAMA Neurol. 2026. PMID: 42043830. doi:10.1001/jamaneurol.2026.0865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。